NeuroPace held an Investor Day with presentations by management focused on the Company’s vision for its unique RNS technology, including its market, product and clinical development strategies for the RNS System in addressing patients suffering from drug-resistant epilepsy.
Management was joined by guest speakers, including key opinion leaders Mark Richardson, MD, PhD, Associate Professor, Neurological Surgery at Harvard Medical School, and Vikram Rao, MD, PhD, Associate Professor, Neurology at UCSF Weill Institute for Neurosciences, to discuss the current role of RNS therapy for drug-resistant epilepsy treatment, the power of the RNS data, and future AI-powered applications; and Mike McKenna, MSW, Senior Patient Engagement Specialist at NeuroPace, to discuss the impact of the RNS System on persons with epilepsy.